ISGD 2026 Clinical Trials Summit Abstract Submission

Abstract Submission

2026 Clinical Trials Summit
Thank you for your interest in the 2026 ISGD Clinical Trials Summit!

Please review the abstract submission guidelines below and if you have any questions, please contact ctsummit@is-gd.org.

The abstract submission deadline is May 15, 2026.

Use the "Save" button at the end of the form to save your work and return later, if necessary.
Submission Information
Theme*

Transforming Clinical Trial Design and Evidence GenerationCross-Sector Collaboration and Regulatory AlignmentOperational Excellence and Real-World Implementation
Preferred presentation format (select all that apply):*

PosterShort talk
If accepted, may we include this abstract in a published collection of abstracts from the conference?*

YesNo
If accepted, may we include your poster in an online gallery of posters from the conference?*

YesNoDuring conference only, but not in an enduring archival gallery
Has this work been previously published or presented at a major meeting?*

YesNo
If so, provide details of publication/presentation:
Title*
Submitting Author Name*

First NameLast Name
Submitting Author Email*
example@example.com

Full Author List

	First Name	Last Name	Institution	City	Country	Email
Author 1
Author 2
Author 3
Author 4
Author 5
Author 6
Author 7
Author 8

Any additional authors (first name, last name, institution, city, country) or notes on contributions (e.g. co-first, co-senior)
Please confirm that all listed authors fulfill the author criteria outlined in ICMJE guidelines:
1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or reviewing it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
I confirm that all authors meet the stated criteria.
Abstract Content

Please keep total content to 350 words or less.
Introduction*
Methods*
Results/Findings*
Conclusion/Actionability*
Ethical Statement

Please complete all relevant fields
Human Subjects Research
Please confirm that patient privacy is protected and patient data is handled in compliance with relevant regulations and guidelines.*

YesN/A (no patient data)
Please confirm that all human subjects research was conducted in alignment with the Declaration of Helsinki.*

YesN/A (no human subjects)
Artificial Intelligence (AI) disclosure: Describe any AI tools used in manuscript production and what was produced by AI.
Please attest to the following statement on author responsibility.
- The authors of this abstract accept responsibility for the accuracy, integrity, and originality of the work, regardless of technologies used.
- The authors have carefully reviewed and edited all materials produced through the use of AI.
- There is no plagiarism of text or images in the work. All quoted material is properly attributed.
I agree with the statement on author responsibility.
Disclosure of Interests

Please complete for presenting author.
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your abstract. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the work. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your abstract pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.*

	Name all entities with whom you have this relationship or indicate "none" in right-hand column	Specifications/Comments (e.g., if payments were made to you or to your institution)	None
1. All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.
2. Grants or contracts from any entity (if not indicated in item #1 above).
3. Royalties or licenses
4. Consulting fees
5. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events
6. Payment for expert testimony
7. Support for attending meetings and/or travel
8. Patents planned, issued or pending
9. Participation on a Data Safety Monitoring Board or Advisory Board
10. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid
11. Stock or stock options
12. Receipt of equipment, materials, drugs, medical writing, gifts or other services
13. Other financial or non-financial interests

Should be Empty:

Abstract Submission

Submission Information

Abstract Content

Ethical Statement

Disclosure of Interests